Literature DB >> 9427013

Molecular neurobiology of Alzheimer's disease (syndrome?).

G S Zubenko1.   

Abstract

Alzheimer's disease (AD) is the most common cause of mental impairment in late life and is estimated to afflict nearly half of older adults who live beyond age 85. Although progressive dementia is a cardinal feature of patients with AD, age at symptomatic onset, rate of progression, and specific signs and symptoms vary widely. This clinical heterogeneity appears to arise in part from interindividual differences in the precise molecular events that contribute to the pathophysiology of AD, as well as from nonuniform or multifocal patterns of brain degeneration that occur during the early to middle stages of dementia. The goals of this review are to cover the substantial progress that has been made over the past 5 years in the major thematic areas of research in AD and to assemble these individual findings into a more integrated picture of the pathophysiology of the disorder. The results may have important implications for the treatment or prevention of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427013     DOI: 10.3109/10673229709000303

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  7 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia.

Authors:  Kelly A Ryan; Dustin Hammers; Angeline DeLeon; Hande Bilen; Kirk Frey; James Burke; Roger Albin; Nancy Barbas; Judith Heidebrink; Bruno Giordani
Journal:  J Clin Neurosci       Date:  2017-06-07       Impact factor: 1.961

3.  D10S1423 identifies a susceptibility locus for Alzheimer's disease (AD7) in a prospective, longitudinal, double-blind study of asymptomatic individuals: results at 14 years.

Authors:  George S Zubenko; Hugh B Hughes; Wendy N Zubenko
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

4.  Differential hippocampal gene expression and pathway analysis in an etiology-based mouse model of major depressive disorder.

Authors:  George S Zubenko; Hugh B Hughes; Rick M Jordan; James Lyons-Weiler; Bruce M Cohen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2014-07-25       Impact factor: 3.568

5.  Predicted gene sequence C10orf112 is transcribed, exhibits tissue-specific expression, and may correspond to AD7.

Authors:  George S Zubenko; Hugh B Hughes
Journal:  Genomics       Date:  2009-01-10       Impact factor: 5.736

Review 6.  Optimal treatment of Alzheimer's disease psychosis: challenges and solutions.

Authors:  Jeremy Koppel; Blaine S Greenwald
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-24       Impact factor: 2.570

7.  Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis.

Authors:  J J Gomar; G Tan; J Halpern; M L Gordon; B Greenwald; J Koppel
Journal:  Transl Psychiatry       Date:  2022-02-26       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.